Comparative Pharmacology
Head-to-head clinical analysis: METRONIDAZOLE HYDROCHLORIDE versus SOLOSEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRONIDAZOLE HYDROCHLORIDE versus SOLOSEC.
METRONIDAZOLE HYDROCHLORIDE vs SOLOSEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Upon anaerobic reduction of the nitro group, forms toxic intermediates that damage bacterial DNA and inhibit nucleic acid synthesis.
Secnidazole is a nitroimidazole antibiotic that exerts its bactericidal activity by entering the bacterial cell and inhibiting DNA synthesis. The nitro group of secnidazole is reduced intracellularly to form free radicals and other reactive intermediates that damage bacterial DNA.
Intravenous: 500 mg every 6 hours or 500 mg every 8 hours. Typical adult dose: 500 mg IV every 6 hours.
2 g orally as a single dose for trichomoniasis.
None Documented
None Documented
7-8 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment.
Terminal elimination half-life approximately 8-12 hours in patients with normal renal function; may be prolonged in renal impairment
Renal 60-80% as unchanged drug and metabolites; fecal 6-15%; biliary minor.
Renal: approximately 75% as unchanged drug; fecal/biliary: minor (estimated <10%)
Category A/B
Category C
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic